Skip to main content

Eli Lilly and Company ratios

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

In fiscal 2025 (the year to 31 Dec 2025), Eli Lilly and Company had an operating margin of 40.9%, a return on equity of 101%, a return on invested capital of 34.4%.

From Eli Lilly and Company's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Eli Lilly and Company ratios, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin77.2%78.5%80.6%81.1%79.1%78.8%78.8%74.9%74.8%73.1%77.7%78.2%78.8%77.7%74.2%76.8%79.2%81.3%83.0%
Operating margin—−5.3%25.7%30.1%22.8%24.7%26.2%16.1%14.8%16.8%12.7%18.3%25.4%30.9%22.9%25.0%20.6%29.9%40.9%
Net margin15.8%−10.2%19.8%22.0%17.9%18.1%20.3%12.2%12.1%12.9%−1.0%15.0%37.3%25.2%19.7%21.9%15.4%23.5%31.7%
Free cash flow margin21.9%31.2%16.4%26.7%27.0%19.5%20.4%16.8%9.5%18.0%22.7%20.1%17.0%20.8%21.4%20.1%2.3%8.3%13.8%
Return on equity—−30.8%53.2%46.2%33.5%28.9%28.9%14.5%16.1%19.2%−1.6%30.2%134%150%76.4%63.6%48.9%84.6%101%
Return on assets—−2.9%16.0%18.7%13.9%12.4%13.8%7.0%7.1%7.8%4.8%7.6%12.0%15.1%12.3%13.3%9.9%15.8%22.3%
Return on capital employed—−6.7%30.4%30.9%22.7%22.0%23.1%11.9%10.9%12.9%8.7%12.6%19.0%24.6%19.1%21.6%20.4%30.9%41.7%
Return on invested capital—−3.9%23.7%32.2%22.5%19.3%21.1%9.8%10.2%11.9%7.3%12.2%18.9%22.6%18.9%20.2%14.7%23.4%34.4%
Current ratio—0.951.902.141.601.551.471.221.531.371.321.731.161.401.231.050.941.151.58
Debt to equity—1.550.700.560.630.380.300.520.550.741.181.056.113.061.961.592.442.441.65
Net debt / EBITDA—104.760.310.030.23−0.02−0.020.710.810.841.370.521.951.521.701.702.732.061.28
Interest coverage—−4.7321.5037.4829.7631.4237.7921.1618.3119.2211.2416.1814.1521.1119.1221.5314.4917.2429.75
Cash conversion138%−306%82.5%122%151%108%101%138%78.8%139%−2224%133%45.7%82.5%108%91.8%15.1%35.5%43.5%
Dividend payout62.8%—49.7%42.7%50.1%53.5%45.3%87.9%88.3%78.8%—71.5%29.0%43.4%55.3%56.6%77.7%44.2%26.1%
SBC / Revenue−1.5%1.3%1.7%1.0%0.6%0.6%0.6%0.8%1.1%1.2%1.4%1.3%1.4%1.3%1.2%1.3%1.8%1.4%1.0%

Quarterly

Eli Lilly and Company ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin80.9%80.9%80.8%81.0%82.2%82.5%84.3%82.9%82.5%81.9%85.8%83.9%
Operating margin28.3%31.0%32.7%15.6%38.9%29.1%45.2%42.1%44.0%45.0%39.1%35.3%
Net margin23.4%25.6%26.3%8.5%32.6%21.7%36.4%31.7%34.4%37.4%30.9%26.4%
Free cash flow margin−14.8%2.0%2.1%20.6%7.2%1.2%8.9%38.3%3.5%15.2%33.8%33.7%
Return on equity20.3%17.5%21.9%6.8%30.9%17.5%31.0%23.5%25.0%23.7%20.9%16.0%
Return on assets3.6%3.8%4.3%1.4%5.9%3.3%5.8%5.0%6.1%6.4%4.8%4.5%
Return on capital employed7.2%6.0%8.3%3.5%10.5%6.2%11.4%9.9%11.0%11.2%9.5%8.5%
Return on invested capital5.3%5.4%6.7%2.2%8.8%4.9%9.2%8.6%9.5%9.5%7.4%6.7%
Current ratio0.941.351.111.271.151.371.281.551.581.501.351.39
Debt to equity2.442.052.132.192.442.442.181.791.651.391.621.23
Net debt / EBITDA7.717.586.2012.285.468.484.854.134.034.044.834.87
Interest coverage19.1515.1220.169.2423.4215.1828.2241.2738.13———
Cash conversion−63.1%8.0%8.1%243%22.2%5.7%24.6%121%10.2%40.7%109%127%
Dividend payout46.5%52.1%39.5%121%26.5%48.8%23.8%24.1%20.3%20.9%21.8%23.9%
SBC / Revenue1.3%1.8%1.9%1.2%1.0%1.2%1.2%0.9%0.7%0.8%0.9%0.8%

The main figures as JSON and plain text. See data and methodology.

LLY in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.